Valeant's Brodalumab Faces Conflicting FDA Views On Suicide Risk
Executive Summary
Advisory committee will hear agency reviewers' different conclusions on plaque psoriasis drug's approvability due to potential psychiatric effects and whether a REMS can help mitigate the risks.
You may also be interested in...
Post-Marketing Registry, Suicidality Warning Could Be Paradox For Siliq
Labeling for Valeant’s pending plaque psoriasis treatment might warn about the potential for suicide; if that's effective, though, will the company be able to enroll meaningful numbers of patients in its registry that aims for a definitive answer?
Valeant's Siliq Clears FDA Panel But Faces Prospect Of Post-Marketing Registry
Agency's advisors were divided on whether Valeant's proposal for voluntary registry would suffice or whether mandatory program under REMS was needed to better assess risk of suicide and suicidal behavior with psoriasis drug.
Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017
Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.